Brain zaps for depression? DBS device tested in 46 patients
NCT ID NCT03653858
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether deep brain stimulation (DBS) can help people with severe depression that hasn't responded to other treatments. 46 patients received either active DBS or a sham (inactive) device. The goal was to see if DBS reduces depression symptoms safely.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- deep brain stimulation (DBS) device
- What this could lead to
- If it works, this could offer a new option for people with severe depression that hasn't improved with other treatments.
- What could go wrong
- This is a small, early-stage trial with only 46 participants. The effects may not be large or lasting, and brain surgery carries risks like infection or bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
46 people
The number who actually took part.
- Started
-
Sep 2018
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Major depression (MD), severe, unipolar, or bipolar in an acute depression episode. 2. German mother tongue or fluent. 3. Male or female patients ≥20 and ≤75 years. 4. Hamilton Depression Rating Scale (HDRS-28) score of \>21. 5. Global Assessment of Function (GAF) score of \<45. 6. At least 4 episodes of depression or one chronic episode \>2 years. 7. Failure to respond to 1. adequate trials of primary antidepressants from at least 3 different classes (\>5 weeks at the maximum recommended or tolerated dose) and 2. adequate trials of augmentation/combination of a primary antidepressant (\>3 weeks at the usually recommended or maximum tolerated dose) using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant) and 3. an adequate trial of electroconvulsive therapy (ECT) (\>6 treatments) and an adequate trial of individual psychotherapy (\>20 sessions with an experienced psychotherapist). 8. Able to give written informed consent. 9. Compliance to participate in the study. 10. Drug free or on stable drug regimen at least 6 weeks before study entry. Exclusion Criteria: 1. Current or past non-affective psychotic disorder. 2. Any current clinically significant neurological disorder or medical illness affecting brain function, other than motor tics or Gilles de la Tourette syndrome. 3. Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI), any contraindications to perform a planned MRI to visualize the slMFB. 4. Any surgical contraindications to undergoing DBS like deformed or displaced or not discernable target region, scarring after brain disease (infarction), need for continuous anticoagulation that cannot be bridged in order to obtain normal coagulation, present risks for anesthesia or any brain or scalp injury (even after intracranial surgery). 5. Current or unstably remitted substance abuse (aside from nicotine). 6. Pregnancy, women of childbearing age not using effective contraception and breast feeding women. 7. History of severe personality disorder. 8. Acute suicidal ideation. 9. Patients with advanced stage cardiovascular disease. 10. Patients under immunosuppressive or chemo therapy because of malignant disease. 11. Patients who had previous intracranial surgery. 12. Patients who are currently under DBS therapy or have implanted any kind of stimulator already. 13. Patients with aneurysm clips. 14. Patients with cochlear implants. 15. Patients with planned diathermy. 16. Persons who are in a relationship of dependence/employment with the sponsor or the investigator. 17. Simultaneous participation or previous participation within 30 days prior to start of screening in a clinical trial involving investigational medicinal product(s) or investigational medical device(s).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Treatment resistant depression are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Université Grenoble Alpes
Grenoble, 38043, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Biotype-assigned augmentation approach in resistant Late-Life depression (BAARD): a randomized controlled trial
- Neural and antidepressant effects of propofol
- Can pairing ketamine with talk therapy beat depression alone?
- Can a psychedelic drug lift depression that won't budge?
- Can a 6,000-Person study unlock personalized depression care for asians?
- A Brain-Stimulation showdown: can accelerated therapy outpace standard care for depression?